Peter A. Friedli
Founder at NEW VENTURETEC AG
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lode Debrabandere | M | 59 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 11 years |
Andreas von Sprecher | M | - | 22 years | |
Kamran Amjadi | M | 60 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | 28 years |
Ingu Yin Chang | M | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Hans Lerch | M | 74 | 17 years | |
D. P. Venkatesh | M | 58 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | 16 years |
Patty Winters | F | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | 20 years |
David L. Clark | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 19 years |
Kevin R. Crowley | M | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Robert R. Becklin | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 years |
Diane Savoie | F | - | 17 years | |
Paul Robbins | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Heather Hill | F | - | 17 years | |
Brad VanWagenen | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 17 years |
Michael Endres | M | - | 7 years | |
Tracy H. Erkkila | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 23 years |
Peter D. Meldrum | M | 77 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Marc Robinson | M | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Charles Whyte | M | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Chad Bello | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 years |
Kevin Crowley | - | - |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Tadashi Hirose | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
David John Savage | M | 63 |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Kimberly V. Rogers | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 20 years |
Tracy L. Slavin | F | 54 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | 24 years |
William Watkins | M | 71 |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | 15 years |
Walter A. Gilbert | M | 92 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Kenneth P. Lawler | M | 65 |
Vertical Circuits, Inc.
Vertical Circuits, Inc. SemiconductorsElectronic Technology Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products. | - |
Jeffrey Levin | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bobby Dwayne Montgomery | M | 56 | 2 years | |
Mehrdad Akhavan | M | 61 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
Jim Burns | M | 77 | 7 years | |
Jason Keefer | M | 52 | 5 years | |
Philip R. Jacoby | M | 71 | - | |
Gregory I. Law | M | 57 | 3 years | |
Charles Mills | M | 52 | 9 years | |
Joel Rogers | M | 62 | 2 years | |
Scott Schaffner | M | 54 | - | |
John Hoffman | M | 65 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
Felix Gutzwiller | M | 76 | 12 years | |
David A. Dresner | M | - | 1 years | |
Alan K. Smith | M | 68 | 2 years | |
David L. White | M | 55 | 1 years | |
Uwe Sommer | M | - | 1 years | |
Cary Claiborne | M | 64 | 3 years | |
Charles Reinhart | M | 63 | 1 years | |
Christopher R. Alder | M | - | - | |
Linda Palczuk | F | 62 | 1 years | |
Yves Huwyler | M | 51 | - | |
Willi Miesch | M | 60 | 1 years | |
Samson Tom | M | 51 | 1 years | |
Hans Klingemann | M | 74 | 4 years | |
Michael Zagger | M | - | - | |
David A. Samuels | M | 62 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
Thomas M. Brandt | M | 72 | 2 years | |
Frank D. Czworka | M | 55 | 5 years | |
Thomas Knapp | M | 71 | 2 years | |
Gregory H. Barnhill | M | 71 | 6 years | |
Michelle LeRoux Williams | M | 50 | 13 years | |
Jay Moyes | M | 70 | 11 years | |
Linda L. Chang | F | 57 | 1 years | |
Rich W. Hunt | M | - | 1 years | |
Moya M. Daniels | F | 55 | 2 years | |
Alla Danilkovitch | M | 60 | 16 years | |
Harry E. Carmitchel | M | 73 | 5 years | |
Matthew Paul Neumayer | M | - | 6 years | |
Rodrigo Alberto Avendano | M | - | 1 years | |
Sean Deson | M | - |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
Daniel Marshak | M | 67 | 6 years | |
Laine Dyess | M | - | 5 years | |
Mehmet C. Oz | M | 63 | 2 years | |
James Black | M | - | - | |
Robert J. Deans | M | 71 | 3 years | |
Stephen W. Potter | M | 67 | 1 years | |
Douglas Jacobstein | M | - | - | |
Katherine Turner | F | - | 2 years | |
Linda N. Liu | M | 57 | 1 years | |
Rodney L. Monroy | M | - | - | |
Therésa K. Dixon | F | - | 2 years | |
Adrian P. Mollo | M | 49 | - | |
John Kinzer | M | 55 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | 2 years |
Jonathan Hopper | M | 61 | 2 years | |
Alastair M. Mackay | M | - | 9 years | |
Earl Fender | M | 77 | 2 years | |
Norman W. Barton | M | - | 2 years | |
Jim C. Williams | M | 80 | 1 years | |
Amori Langstaff | F | 53 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
Donald W. Fallon | M | 69 | 1 years | |
Ira Becker | M | 56 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | - |
David Jodoin | M | 60 |
Invenda Corp.
Invenda Corp. Advertising/Marketing ServicesCommercial Services Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 87 | 96.67% |
Switzerland | 3 | 3.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter A. Friedli
- Personal Network